← All trials
NCT03752398
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2019
- Primary completion
- Sep 30, 2024
- Completion date
- Mar 31, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 144
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Nasopharyngeal Carcinoma
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Colorectal Neoplasms
- Endometrial Neoplasms
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.